China Power (02380): Jianxin Investment will reduce the registered capital of Xinyuan Green Energy to 1.666 billion yuan.
China Power (02380) announced that on February 12, 2026, Jianxin Investment, the Company and Xinyuan Green Energy (a non-wholly owned subsidiary of the Company) entered into a capital reduction agreement. Jianxin Investment will exit all its equity in Xinyuan Green Energy through a targeted reduction of Xinyuan Green Energy's registered capital of RMB 1.666 billion (equivalent to approximately HK$1.8716 billion) at a price of RMB 2.006 billion (equivalent to approximately HK$2.254 billion).
China Power (02380) announced that on February 12, 2026, Jianxin Investment, the company, and Xinyuan Green Energy (a subsidiary of the company) entered into a capital reduction agreement. Jianxin Investment will reduce its equity in Xinyuan Green Energy by way of capital reduction to RMB 1.666 billion (equivalent to approximately HKD 1.8716 billion), exiting all its shares in Xinyuan Green Energy for a consideration of RMB 2.006 billion (equivalent to approximately HKD 2.254 billion).
Following the capital reduction, the registered capital of Xinyuan Green Energy will decrease from RMB 3.666 billion (equivalent to approximately HKD 4.119 billion) to RMB 2 billion (equivalent to approximately HKD 2.247 billion). The company's equity in Xinyuan Green Energy will increase from 54.56% to 100%.
After Jianxin Investment exits Xinyuan Green Energy, it will become a wholly-owned subsidiary of the company. The company is optimistic about the future development of Xinyuan Green Energy and will have the right to enjoy all future profits generated by Xinyuan Green Energy, thereby increasing the contribution to the company's shareholders' net profit.
Related Articles

Shenwan Hongyuan Group (06806) successfully issued 4 billion yuan in corporate bonds.

CSPC Innovation Pharmaceutical (300765.SZ) subsidiary SYS6023 antibody-drug conjugate obtains approval for clinical trials.

SINOPEC KANTONS (00934) signs exclusive operating agreement with Caofeidian Port Group.
Shenwan Hongyuan Group (06806) successfully issued 4 billion yuan in corporate bonds.

CSPC Innovation Pharmaceutical (300765.SZ) subsidiary SYS6023 antibody-drug conjugate obtains approval for clinical trials.

SINOPEC KANTONS (00934) signs exclusive operating agreement with Caofeidian Port Group.

RECOMMEND

Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026

Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026

Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026


